2025
SJR Q2
JCR Q2 · 2,4
320 matched articles
SCIE
Journal detail
Leukemia Research
- Publisher
- Elsevier Ltd
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
0145212618735835
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,876
- Quartile Q2
- H-Index 100
- Cites/doc 1,92
- Docs (3y) 349
- Cites (3y) 700
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 2,4
- 5Y JIF 2,5
- JCI 0,52
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Cancer Research Q3
- Hematology Q2
- Oncology Q2
WoS categories
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 0,876 | 2,4 | 2,5 | 0,52 | Q3 | 100 |
| 2024 | Q2 | Q3 | 0,784 | 2,2 | 2,3 | 0,47 | Q3 | 98 |
| 2023 | Q2 | Q3 | 0,694 | 2,1 | 2,3 | 0,48 | Q3 | 98 |
| 2022 | Q2 | Q3 | 0,673 | 2,7 | 2,5 | 0,49 | Q3 | 98 |
| 2021 | Q2 | Q3 | 0,865 | 3,7 | 2,9 | 0,56 | Q3 | 98 |
| 2020 | Q2 | Q3 | 0,853 | 3,2 | 2,7 | 0,54 | Q3 | 98 |
| 2019 | Q2 | Q3 | 0,78 | 2,2 | 2,2 | 0,54 | Q3 | 98 |
| 2018 | — | Q3 | — | 2,1 | 2,1 | 0,55 | Q2 | — |
| 2017 | Q2 | Q3 | 1,063 | 2,3 | 2,3 | 0,6 | Q2 | 98 |
| 2016 | Q2 | Q3 | 0,997 | 2,5 | 2,4 | — | — | 98 |
| 2015 | Q2 | Q3 | 1,049 | 2,6 | 2,5 | — | — | 98 |
| 2014 | Q2 | Q3 | 1,047 | 2,4 | 2,4 | — | — | 98 |
| 2013 | Q2 | Q2 | 1,072 | 2,7 | 2,5 | — | — | 98 |
| 2012 | Q2 | Q2 | 0,885 | 2,8 | 2,6 | — | — | 98 |
| 2011 | Q2 | Q2 | 0,963 | 2,9 | 2,5 | — | — | 98 |
| 2010 | Q2 | Q2 | 0,777 | 2,6 | 2,3 | — | — | 98 |
| 2009 | — | Q3 | — | 2,4 | 2,2 | — | — | — |
| 2008 | — | Q3 | — | 2,4 | 2,2 | — | — | — |
| 2007 | — | Q2 | — | 2,6 | 2,3 | — | — | — |
| 2006 | — | Q2 | — | 2,5 | — | — | — | — |
| 2005 | — | Q2 | — | 2,4 | — | — | — | — |
| 2004 | — | Q2 | — | 2,2 | — | — | — | — |
| 2003 | — | Q2 | — | 2,3 | — | — | — | — |
| 2002 | — | Q2 | — | 2,1 | — | — | — | — |
| 2001 | — | Q3 | — | 1,5 | — | — | — | — |
| 2000 | — | Q2 | — | 1,5 | — | — | — | — |
| 1999 | — | Q3 | — | 1,1 | — | — | — | — |
| 1998 | — | Q3 | — | 1,3 | — | — | — | — |
| 1997 | — | Q2 | — | 1,3 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | HEMATOLOGY | SCIE | Q2 | Q3 | 51/103 |
| 2025 | ONCOLOGY | SCIE | Q3 | Q3 | 214/333 |
| 2024 | HEMATOLOGY | SCIE | Q3 | Q3 | 51/99 |
| 2024 | ONCOLOGY | SCIE | Q3 | Q3 | 217/328 |
| 2023 | HEMATOLOGY | SCIE | Q3 | Q3 | 58/97 |
| 2023 | ONCOLOGY | SCIE | Q3 | Q3 | 215/322 |
| 2022 | HEMATOLOGY | SCIE | Q3 | Q3 | 52/79 |
| 2022 | ONCOLOGY | SCIE | Q3 | Q3 | 173/241 |
| 2021 | HEMATOLOGY | SCIE | Q3 | Q3 | 41/78 |
| 2021 | ONCOLOGY | SCIE | Q3 | Q3 | 146/245 |
| 2020 | HEMATOLOGY | SCIE | Q3 | Q3 | 44/76 |
| 2020 | ONCOLOGY | SCIE | Q3 | Q3 | 178/242 |
| 2019 | HEMATOLOGY | SCIE | Q3 | Q3 | 51/76 |
| 2019 | ONCOLOGY | SCIE | Q4 | Q3 | 188/244 |
| 2018 | HEMATOLOGY | SCIE | Q3 | Q2 | 53/73 |
| 2018 | ONCOLOGY | SCIE | Q4 | Q3 | 176/230 |
| 2017 | HEMATOLOGY | SCIE | Q3 | Q2 | 41/71 |
| 2017 | ONCOLOGY | SCIE | Q3 | Q3 | 163/223 |
| 2016 | HEMATOLOGY | SCIE | Q3 | — | 37/70 |
| 2016 | ONCOLOGY | SCIE | Q3 | — | 136/217 |
| 2015 | HEMATOLOGY | SCIE | Q3 | — | 38/70 |
| 2015 | ONCOLOGY | SCIE | Q3 | — | 125/213 |
| 2014 | HEMATOLOGY | SCIE | Q3 | — | 40/68 |
| 2014 | ONCOLOGY | SCIE | Q3 | — | 133/211 |
| 2013 | HEMATOLOGY | SCIE | Q2 | — | 28/68 |
| 2013 | ONCOLOGY | SCIE | Q3 | — | 102/203 |
| 2012 | HEMATOLOGY | SCIE | Q2 | — | 31/67 |
| 2012 | ONCOLOGY | SCIE | Q2 | — | 90/197 |
| 2011 | HEMATOLOGY | SCIE | Q2 | — | 27/68 |
| 2011 | ONCOLOGY | SCIE | Q2 | — | 80/196 |
| 2010 | HEMATOLOGY | SCIE | Q3 | — | 35/66 |
| 2010 | ONCOLOGY | SCIE | Q2 | — | 87/185 |
| 2009 | HEMATOLOGY | SCIE | Q3 | — | 34/61 |
| 2009 | ONCOLOGY | SCIE | Q3 | — | 86/166 |
| 2008 | HEMATOLOGY | SCIE | Q3 | — | 34/62 |
| 2008 | ONCOLOGY | SCIE | Q3 | — | 81/143 |
| 2007 | HEMATOLOGY | SCIE | Q2 | — | 29/63 |
| 2007 | ONCOLOGY | SCIE | Q3 | — | 67/132 |
| 2006 | HEMATOLOGY | SCIE | Q2 | — | 30/61 |
| 2006 | ONCOLOGY | SCIE | Q2 | — | 60/127 |
| 2005 | HEMATOLOGY | SCIE | Q2 | — | 26/60 |
| 2005 | ONCOLOGY | SCIE | Q2 | — | 61/123 |
| 2004 | HEMATOLOGY | SCIE | Q2 | — | 25/62 |
| 2004 | ONCOLOGY | SCIE | Q2 | — | 61/123 |
| 2003 | HEMATOLOGY | SCIE | Q2 | — | 21/62 |
| 2003 | ONCOLOGY | SCIE | Q2 | — | 54/120 |
| 2002 | HEMATOLOGY | SCIE | Q2 | — | 23/61 |
| 2002 | ONCOLOGY | SCIE | Q2 | — | 52/114 |
| 2001 | HEMATOLOGY | SCIE | Q3 | — | 30/59 |
| 2001 | ONCOLOGY | SCIE | Q3 | — | 65/107 |
| 2000 | HEMATOLOGY | SCIE | Q2 | — | 29/60 |
| 2000 | ONCOLOGY | SCIE | Q3 | — | 60/103 |
| 1999 | HEMATOLOGY | SCIE | Q3 | — | 35/60 |
| 1999 | ONCOLOGY | SCIE | Q3 | — | 67/105 |
| 1998 | HEMATOLOGY | SCIE | Q3 | — | 31/59 |
| 1998 | ONCOLOGY | SCIE | Q3 | — | 55/104 |
| 1997 | HEMATOLOGY | SCIE | Q3 | — | 31/59 |
| 1997 | ONCOLOGY | SCIE | Q2 | — | 46/102 |